| pegylated liposomal doxorubicin / Generic mfg. |
NCT00005980: Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | 116 | Europe, RoW | pegylated liposomal doxorubicin hydrochloride | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer | 07/02 | | | |
NCT00005991: Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | 76 | US | gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 02/03 | 02/03 | | |
| Completed | 2 | 16 | Europe | Caelyx, liposomal doxorubicin, endoxan, cyclophosphamide | Universitaire Ziekenhuizen KU Leuven | Breast Cancer, Elderly | | 04/07 | | |
NCT00779129: A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) |
|
|
| Completed | 2 | 70 | Canada | Pegylated Lyposomal Doxorubicin, SCH 200746, Cyclophosphamide | Merck Sharp & Dohme LLC, Princess Margaret Hospital, Canada | Breast Neoplasm | 08/07 | 08/07 | | |
NCT00004888: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer |
|
|
| Completed | 2 | 84 | US | pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox, docetaxel, RP 56976, Taxotere, TXT, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Breast Cancer, Stage IV Breast Cancer | 04/08 | 05/09 | | |
NCT00524459: Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery |
|
|
| Terminated | 2 | 6 | US | docetaxel, pegylated liposomal doxorubicin hydrochloride, conventional surgery, neoadjuvant therapy | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Breast Cancer | 08/08 | | | |
SAKK 24/06, NCT00445406: Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer |
|
|
| Completed | 2 | 43 | Europe | bevacizumab + doxorubin hydrochloride liposme, Bevacizumab | Swiss Group for Clinical Cancer Research | Breast Cancer | 09/08 | 03/09 | | |
NCT00687440 / 2004-003989-15: A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679) |
|
|
| Completed | 2 | 27 | NA | Pegylated Liposomal Doxorubicin, Caelyx, Docetaxel, Taxotere, Trastuzumab | Merck Sharp & Dohme LLC, MDS Pharma Services | Breast Neoplasm | 10/08 | 10/08 | | |
NCT00193037: Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer |
|
|
| Completed | 2 | 102 | US | Liposomal Doxorubicin, Doxil, Docetaxel, Taxotere | SCRI Development Innovations, LLC, Ortho Biotech, Inc., Aventis Pharmaceuticals | Breast Cancer | 12/08 | 11/09 | | |
NCT00524810: Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer |
|
|
| Completed | 2 | 67 | Europe | Pegylated liposomal doxorubicin, Caelyx, Docetaxel, Taxotere | ARCAGY/ GINECO GROUP | Metastatic Breast Cancer | 06/09 | 06/09 | | |
NCT00465673: Liposomal Doxorubicin (Lipo-Dox) in Patients With Brain Metastasis From Breast Cancer |
|
|
| Terminated | 2 | 2 | RoW | Liposomal Doxorubicin | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, TTY Biopharm | Breast Cancer | 07/09 | 07/09 | | |
NCT00499083: Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) |
|
|
| Completed | 2 | 17 | US | therapeutic autologous dendritic cells, aromatase inhibition therapy, endocrine therapy, cyclophosphamide, Cytoxan, doxorubicin hydrochloride, Lipodox, Lipodox 50, and Doxil, paclitaxel, Abraxane, tamoxifen citrate, Nolvadex, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy | University of Nebraska, National Cancer Institute (NCI) | Breast Cancer | 07/09 | 01/10 | | |
NCT00665457: Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery |
|
|
| Terminated | 2 | 3 | US | filgrastim, Neupogen, capecitabine, Xeloda, celecoxib, Celebrex, cyclophosphamide, Cytoxan, Neosar, docetaxel, Docefrez, Taxotere, doxorubicin hydrochloride, Lipodox, Lipodox 50, and Doxil, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging | University of Nebraska, National Cancer Institute (NCI) | Breast Cancer | 07/09 | 07/09 | | |
NCT00303108: Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer |
|
|
| Completed | 2 | 136 | US | Pegylated liposomal doxorubicin, Doxil, Carboplatin, trastuzumab, Herceptin | US Oncology Research, Ortho Biotech, Inc., Tibotec Pharmaceutical Limited | Metastatic Breast Cancer | 03/10 | 06/11 | | |
NCT00550771 / 2006-005780-26: Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048) |
|
|
| Completed | 2 | 181 | NA | doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, PLD, cyclophosphamide, trastuzumab, paclitaxel, pegylated liposomal doxorubicin (SCH 200746) | Merck Sharp & Dohme LLC | Breast Neoplasm | 08/10 | 08/10 | | |
| Completed | 2 | 50 | Europe | Liposomal pegylated doxorubicine, Caelyx | SOLTI Breast Cancer Research Group, Schering-Plough | Breast Cancer | 02/11 | 08/16 | | |
| Completed | 2 | 59 | Europe | pegylated liposomal doxorubicin hydrochloride | ARCAGY/ GINECO GROUP | Breast Cancer | 05/11 | | | |
NCT01206881 / 2008-007951-29: Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast Cancer |
|
|
| Completed | 2 | 45 | Europe | pegylated liposomal doxorubicin, cyclophosphamide, 4 cycles, docetaxel, 4 cycles, trastuzumab, 8 cycles | Herlev Hospital, Rigshospitalet, Denmark, Odense University Hospital, Aarhus University Hospital | Breast Cancer | 05/11 | 06/11 | | |
| Terminated | 2 | 24 | Europe | doxorubicinhydrochloride, Lapatinib | Arbeitsgemeinschaft medikamentoese Tumortherapie, GlaxoSmithKline | Metastatic Breast Cancer | 05/12 | 05/12 | | |
NCT00431795: Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer |
|
|
| Terminated | 2 | 100 | Europe | Pegylated liposomal doxorubicin (Caelyx), Caelyx, Epirubicin, Farmorubicine | Hellenic Oncology Research Group, University Hospital of Crete | Breast Cancer | 06/12 | 06/12 | | |
| Withdrawn | 2 | 0 | Europe | docetaxel, cyclophosphamide, trastuzumab, liposomal doxorubicin | National Cancer Institute, Naples | Breast Cancer | | | | |
NCT00635050: Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin |
|
|
| Completed | 2 | 32 | US | Doxil, Paclitaxel, Cyclophosphamide, Avastin, Bevacizumab (Avastin) | University of Alabama at Birmingham, Ortho Biotech, Inc., Genentech, Inc. | Invasive Breast Cancer | 12/14 | 06/15 | | |
|
NCT00608972: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer |
|
|
| Completed | 2 | 31 | US | Doxil, Carboplatin, Bevacizumab, Avastin | Rutgers, The State University of New Jersey, Rutgers Cancer Institute of New Jersey, National Cancer Institute (NCI) | Metastatic Breast Cancer | 07/15 | 09/15 | | |
NCT00004925: Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | | US | trastuzumab, pegylated liposomal doxorubicin hydrochloride | Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) | Breast Cancer | 08/03 | 08/03 | | |
NCT00006825: Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer |
|
|
| Completed | 1/2 | | US | trastuzumab, pegylated liposomal doxorubicin hydrochloride | NYU Langone Health, National Cancer Institute (NCI) | Breast Cancer | 07/04 | | | |
NCT00237627: Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 107 | US | PS-341, Doxil, pegylated liposomal doxorubicin, Velcade, Bortezomib | UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI) | Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 12/06 | 01/10 | | |
NCT00331552: Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer |
|
|
| Completed | 1/2 | 30 | US | pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, Evacet, LipoDox, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, Enduxan, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, monoclonal antibody c-erb-2, monoclonal antibody HER2 | University of Washington, National Cancer Institute (NCI) | HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 02/11 | 02/12 | | |
NCT00182767: Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer |
|
|
| Completed | 1/2 | 45 | US | ixabepilone, BMS-247550, epothilone B lactam, Ixempra, pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox | National Cancer Institute (NCI) | Fallopian Tube Cancer, Female Reproductive Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer | 04/12 | 05/14 | | |
| Terminated | 1/2 | 15 | RoW | Lapatinib, Tykerb, Lipo-Dox, Liposomal doxorubicin hydrochloride | China Medical University Hospital | Metastatic Breast Cancer | 09/14 | 09/14 | | |
